Loomis Sayles & CO L P Neurocrine Biosciences Inc Transaction History

Loomis Sayles & CO L P

$76.2 Billion
Q3 2024

A detailed history of Loomis Sayles & CO L P transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Loomis Sayles & CO L P holds 150,337 shares of NBIX stock, worth $21.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

150,337

Previous 160,270 6.2%

Holding current value

$21.2 Million

Previous $22.1 Million 21.49%

% of portfolio

0.02%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$114.58 - $153.15 $1.14 Million - $1.52 Million	-9,933 Reduced 6.2%	150,337 $17.3 Million
Q2 2024 Aug 13, 2024	SELL	$130.86 - $143.19 $12.4 Million - $13.6 Million	-94,663 Reduced 37.13%	160,270 $22.1 Million
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $122,054 - $134,540	-936 Reduced 0.37%	254,933 $35.2 Million
Q4 2023 Feb 13, 2024	SELL	$106.07 - $132.76 $112,115 - $140,327	-1,057 Reduced 0.41%	255,869 $33.7 Million
Q3 2023 Nov 09, 2023	BUY	$94.02 - $117.1 $4.68 Million - $5.83 Million	49,787 Added 24.04%	256,926 $28.9 Million
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $3.95 Million - $4.63 Million	44,136 Added 27.08%	207,139 $19.5 Million
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $15.3 Million - $20.1 Million	163,003 New	163,003 $16.5 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $13,068 - $15,309	-142 Reduced 6.92%	1,910 $203,000
Q2 2022 Aug 05, 2022	BUY	$75.79 - $100.07 $1,440 - $1,901	19 Added 0.93%	2,052 $200,000
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $147,290 - $192,748	2,033 New	2,033 $191,000
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $21.5 Million - $28.7 Million	-270,355 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $649,021 - $745,794	7,531 Added 2.87%	270,355 $25.9 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $923,543 - $1.06 Million	10,327 Added 4.09%	262,824 $25.6 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $33,013 - $45,013	377 Added 0.15%	252,497 $24.6 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $4.23 Million - $5.28 Million	48,721 Added 23.95%	252,120 $24.2 Million
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $1.72 Million - $2.42 Million	17,892 Added 9.64%	203,399 $19.6 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $1.22 Million - $1.87 Million	14,362 Added 8.39%	185,507 $22.6 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $208,204 - $315,342	-2,772 Reduced 1.59%	171,145 $14.8 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $1.09 Million - $1.49 Million	-12,541 Reduced 6.73%	173,917 $18.7 Million
Q3 2019 Nov 13, 2019	BUY	$83.82 - $101.5 $5.77 Million - $6.98 Million	68,786 Added 58.46%	186,458 $16.8 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $511,820 - $646,647	-7,085 Reduced 5.68%	117,672 $9.94 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $1.58 Million - $2.08 Million	22,744 Added 22.3%	124,757 $11 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $76,586 - $139,407	1,121 Added 1.11%	102,013 $7.28 Million
Q3 2018 Nov 13, 2018	SELL	$98.88 - $125.85 $795,687 - $1.01 Million	-8,047 Reduced 7.39%	100,892 $12.4 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $287,947 - $405,305	-3,824 Reduced 3.39%	108,939 $10.7 Million
Q1 2018 May 11, 2018	SELL	$75.88 - $92.43 $152,974 - $186,338	-2,016 Reduced 1.76%	112,763 $9.35 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $546,084 - $723,914	9,330 Added 8.85%	114,779 $8.91 Million
Q3 2017 Nov 14, 2017	SELL	$47.97 - $61.28 $131,197 - $167,600	-2,735 Reduced 2.53%	105,449 $6.46 Million
Q2 2017 Aug 14, 2017	BUY	N/A	108,184	108,184 $4.98 Million

Others Institutions Holding NBIX

# of Institutions

627

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.

Account

Loomis Sayles & CO L P Neurocrine Biosciences Inc Transaction History